Skip to main content
. 2023 Dec 11;4(12):101312. doi: 10.1016/j.xcrm.2023.101312

Figure 1.

Figure 1

I-SPY 2 Trial design, RPPA workflow, and patient distribution

(A) I-SPY 2 Trial schematic.6

(B) Patient number distribution by trial arm and HR/HER2 status in the reverse phase protein array (RPPA) dataset. Ctr, control; N, neratinib; PD1-inh, PD1 inhibitor; TDM1/P, TDM1 + pertuzumab; VC, veliparib + carboplatin.

(C) RPPA workflow (image modified from Loebke et al.9).